Article · 2011
Editorial Board Member
Cara J Westmark
Department of Pathology & Laboratory Medicine, University of Wisconsin-Madison, USA
About
As published by the journal they serve.
Dr Cara Westmark is an Associate Scientist at the Waisman Center for Developmental Disabilities at the University of Wisconsin Madison. Her current research examines the role of genetic and environmental factors on the expression of amyloid precursor protein APP and betaamyloid A61538. In transgenic mouse models of neurological disorders. She has demonstrated that APP/A61538. levels are altered in Fragile X syndrome and that many FXS phenotypes can be rescued in a mouse model of the disorder by genetically reducing APP/A61538. These data suggest that therapies studied for the treatment of Alzheimer’s disease AD may be beneficial in the treatment of FXS .She has also demonstrated a strong association between APP/A61538. overexpression and lower seizure threshold which has important implications for the treatment of seizurerelated disorders such as AD FXS and Down syndrome. Her most recent work has demonstrated a strong association between dietary phytoestrogen consumption elevated A and reduced seizure threshold.
Journals they serve
The seats these journals name them in.
- Translational MedicineEditorial Board Member
Articles we hold
Articles in the journals they serve whose byline carries this name.
Article · 2013
Soy Infant Formula may be Associated with Autistic Behaviors
Article · 2012
Can mGluR5 antagonists be utilized to reduce beta-amyloid levels in Alzheimer’s disease and other neurological disorders
Article · 2011
Effect of Anticoagulants on Amyloid®-Protein Precursor and Amyloid Beta Levels in Plasma
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
